SequelSEC

Oric Pharmaceuticals, Inc. ORIC

Pharmaceutical Preparations · CIK 0001796280 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$45.30M
Fiscal year ended 2026-06-30
Free cash flow
-$31.96M
Fiscal year ended 2026-06-30

Oric Pharmaceuticals, Inc. (ORIC) reported net income of -$41.49M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Oric Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Oric Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$45.30M-$39.62M-$34.55M-$36.67M-$39.06M-$32.72M-$39.57M-$38.32M-$36.02M-$28.99M
Net income-$41.49M-$35.77M-$30.50M-$32.59M-$36.36M-$30.02M-$36.31M-$34.57M-$31.96M-$25.01M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 108.01Mshares 105.47MUnavailableshares 98.95Mshares 78.13Mshares 71.04MUnavailableshares 70.54Mshares 70.35Mshares 67.35M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.38$-0.34Unavailable$-0.33$-0.47$-0.42Unavailable$-0.49$-0.45$-0.37
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.00M$8.18M$8.70M$7.90M$8.52M$8.08M$7.60M$7.12M$7.08M$7.03M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Oric Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$37.48M$56.40M$45.67M$49.67M$75.86M$49.33M$59.41M$44.23M$49.83M$56.36M
Total assets$404.68M$436.76M$408.89M$431.19M$346.86M$242.86M$274.14M$302.07M$328.91M$350.79M
Current assets$273.70M$290.23M$288.47M$295.59M$291.12M$211.43M$262.25M$279.43M$294.60M$324.08M
Total liabilities$23.43M$21.20M$24.53M$24.27M$22.86M$23.12M$31.02M$28.08M$26.51M$22.14M
Current liabilities$20.76M$17.77M$20.42M$20.18M$18.05M$17.62M$24.85M$21.25M$19.54M$15.21M
Total equity incl. NCI$381.26M$415.56M$384.36M$406.92M$324.00M$219.74M$243.12M$273.99M$302.40M$328.64M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.87M$2.90M$3.82M$2.90M$3.13M$5.16M$1.55M$4.25M$2.31M$2.99M

Cash flow

Oric Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$31.60M-$32.44M-$22.48M-$25.11M-$30.84M-$32.53M-$28.05M-$28.80M-$25.62M-$30.19M
Capital expenditures$356.00K$2.00K$227.00K$35.00K$63.00K$387.00K$219.00K$418.00K$333.00K$218.00K
Investing cash flow$11.86M-$17.98M$16.98M-$110.54M-$76.93M$22.45M$42.66M$23.07M$18.28M-$61.87M
Financing cash flow$828.00K$61.14M$1.50M$109.45M$134.30M$11.00K$575.00K$126.00K$816.00K$125.03M
Net change in cash-$18.91M$10.73M-$4.00M-$26.20M$26.53M-$10.07M$15.18M-$5.60M-$6.53M$32.98M
Stock-based compensation$7.09M$6.90M$6.28M$5.63M$6.57M$6.55M$5.20M$5.06M$5.00M$4.96M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Oric Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$31.96M-$32.44M-$22.71M-$25.15M-$30.90M-$32.92M-$28.27M-$29.22M-$25.96M-$30.40M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio13.19x16.33x14.13x14.65x16.13x12.00x10.56x13.15x15.08x21.31x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ORIC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-23View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-05View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.